Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.72 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 5/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.40 |
| ▸ | ERBB3 | P21860 | 5/20 | 0.40 |
| ▸ | ERBB4 | Q15303 | 5/20 | 0.40 |
| ▸ | TEK | Q02763 | 4/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | RET | P07949 | 2/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14537338 | 0.90 | NTRK1 (0.56) | NTRK1NTRK2PDGFRBEGFRERBB2 | |
| SCHEMBL1924932 | 0.86 | NTRK1 (0.72) | NTRK1NTRK2PDGFRBEGFRERBB2 | |
| SCHEMBL14537179 | 0.86 | NTRK2 (0.56) | NTRK1NTRK2PDGFRBEGFRERBB2 | |
| SCHEMBL1924646 | 0.85 | NTRK1 (0.73) | NTRK1NTRK2PDGFRBEGFRERBB2 | |
| SCHEMBL1924757 | 0.84 | NTRK1 (1.00) | NTRK1NTRK2PDGFRBEGFRERBB2 | |
| SCHEMBL14537181 | 0.83 | AURKB (0.51) | NTRK1NTRK2PDGFRBEGFRERBB2 | |
| SCHEMBL1925471 | 0.83 | NTRK1 (0.86) | NTRK1NTRK2PDGFRBEGFRERBB2 | |
| SCHEMBL1924665 | 0.82 | NTRK1 (0.84) | NTRK1NTRK2PDGFRBEGFRERBB2 | |
| SCHEMBL1925247 | 0.82 | NTRK1 (0.88) | NTRK1NTRK2PDGFRBEGFRERBB2 | |
| SCHEMBL1924937 | 0.82 | NTRK1 (0.88) | NTRK1NTRK2PDGFRBEGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514435-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| WO-2007061882-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | NTRK1 3/4885NTRK2 1/4885PDGFRB 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.